Sjöström, Martin

Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up

Tutzauer, J., Sjöström, M., Holmberg, E., Karlsson, P., Killander, F., Leeb-Lundberg, L. M. F., Malmström, P., Niméus, E., Fernö, M., & Jögi, A. (2022) · British Journal of Cancer

Breast Cancer Treatment StudiesCancer, Hypoxia, and Metabolism

Cited by 53

An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer

Das, R., Sjöström, M., Shrestha, R., Yogodzinski, C., Egusa, E. A., Chesner, L. N., Chen, W. S., Chou, J., Dang, D. K., Swinderman, J. T., et al. (2021) · Nature Communications

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 38

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer

Li, H., Melnyk, J. E., Fu, B. X. H., Shrestha, R., Zhang, M., Sjöström, M., Feng, S., Anderson, J. A., Han, W., Chesner, L. N., et al. (2025) · Nature Genetics

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 10

Data from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin

Chu, C. E., Sjöström, M., Egusa, E. A., Gibb, E. A., Badura, M. L., Zhu, J., Koshkin, V. S., Stohr, B. A., Meng, M. V., Pruthi, R. S., et al. (2023)

Bladder and Urothelial Cancer TreatmentsUrinary Bladder and Prostate Research

Cited by 0

Data from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin

Chu, C. E., Sjöström, M., Egusa, E. A., Gibb, E. A., Badura, M. L., Zhu, J., Koshkin, V. S., Stohr, B. A., Meng, M. V., Pruthi, R. S., et al. (2023)

Bladder and Urothelial Cancer TreatmentsUrinary Bladder and Prostate Research

Cited by 0